Magic mushroom compound tested to help curb opioid cravings
NCT ID NCT04161066
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This early-phase study is testing whether adding two doses of psilocybin (the active ingredient in magic mushrooms) with counseling is safe for adults with opioid use disorder who are already taking buprenorphine/naloxone (a standard medication). The study will monitor side effects, withdrawal symptoms, and changes in opioid cravings. Only 10 people will participate, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin (the active ingredient in magic mushrooms) given with counseling
What this could lead to
If it works, this could point toward a way to reduce opioid cravings and improve quality of life for people already on medication for opioid use disorder.
What could go wrong
This is a very early, small phase 1 study with only 10 people, so results may not apply widely. Psilocybin can cause intense psychological effects and is not yet proven safe or effective for this condition.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.